Jump to content

Massachusetts v. Purdue

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Oceanflynn (talk | contribs) at 21:56, 2 February 2019 (expanding). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Suffolk County v. Purdue New York v Purdue Pharma LP et al is a No. 400016/2018 lawsuit filed on August 14, 2018 in the New York State Supreme Court in Suffolk County, in which New York State sued the Stamford, Connecticut-based company Purdue Pharma LP, which created and manufactures OxyContin, "one of the most widely used and prescribed opioid drugs on the market", and Purdue's owners, the Sacklers[1] accusing them of "widespread fraud and deception in the marketing of opioids, and contributing to the opioid crisis, the nationwide epidemic that has killed thousands."[2] Purdue denied the allegations.

The case

In June 1, 2018, Massachusetts Attorney General Maura Healey notified notified Richard Stephen Sackler (born March 1945), former Purdue CEO and current director, son of Purdue's co-founder Raymond Sackler (1920 – 2017), Beverly Sackler — Richard' wife and former director, David Sackler, Ilene Sackler Lefcourt, Jonathan Sackler, Kathe Sackler, Mortimer Sackler, Theresa Sackler, Peter Boer, Judith Lewent, Cecil Pickett, Paulo Costa, Ralph Snyderman, John Stewart, Mark Timney, and Craig Landau of her intention to file a 300-page lawsuit accusing Purdue and eight members of the Sackler family and nine other people currently or formerly associated with the company "of misleading doctors and patients about the risks of OxyContin." In December an amended complaint was filed, with 700 redacted sections.[3] Documents filed as part of a lawsuit against the company that ... In an email, that was part of the lawsuit, Healey alleged that "Purdue deceived patients and doctors to get them to prescribe and take the addictive drug." Healey says the complaint saying the 189 paragraphs of the lawsuit should be made public.[4] Healey said in the court complaint that, "Revealing the truth about Purdue's misconduct is important to achieve justice and make sure deception like Purdue's never happens again." On June 16, NBC described Healey's lawsuit that named eight of the Sackler family members, as an "unusual step".[5]

On August 14, 2018, New York State filed a lawsuit Suffolk County v. Purdue New York v Purdue Pharma LP et al No. 400016/2018 at the New York State Supreme Court against the Stamford, Connecticut-based company Purdue Pharma LP, which created and manufactures OxyContin, "one of the most widely used and prescribed opioid drugs on the market", and Purdue's owners, the Sacklers[1] accusing them of "widespread fraud and deception in the marketing of opioids, and contributing to the opioid crisis, the nationwide epidemic that has killed thousands."[2] NPR's WSHU described Suffolk County's August 2018 lawsuit as "rare"—while there are "tens of thousands of opioid lawsuits" in the United States naming Purdue Pharma—the Suffolk County lawsuit specifically names the the Sackler family.[6] According to an October 30, 2017 The New Yorker, there are eight members of the Sackler family, representing three generations, who were serving on Purdue Pharma's board of directors in 2017.[7]

Attorney Paul Hanley, who represents Suffolk County in the lawsuit, said in a radio interview that, the Sackler family "marketed the drug while knowing it was promoting faulty information about it." "[They] were instrumental in developing the entire marketing program for OxyContin, which was predicated upon entirely false science … or no science at all … and because among other things, they have profited grandly from sales of OxyContin."[6][1]

New York State Governor Andrew M. Cuomo and Attorney General Barbara D. Underwood announced on August 14, 2018, that they had filed a lawsuit "against Purdue Pharma L.P., Purdue Pharma Inc., and Pursue Frederick Company, Inc. ("Purdue"), alleging a decades-long and continuing pattern of persistent deceptive and illegal conduct, whereby Purdue's misled prescribers and patients about the risks of its opioids, including OxyContin, intentionally understating the risks and overstating the benefits of these powerful and dangerous drugs".[8]

On December 21, 2018, Massachusetts Attorney General Maura Healey filed an amended complaint to Suffolk County v. Purdue with 700 redacted sections.[3] According to CNN, in a ruling by Suffolk County Superior Judge Janet Sanders, an "unredacted amended complaint must be publicly released by February 1".[4] In response, Purdue Pharma filed a motion on January 30 to stay Judge Sanders' order that "could expose details about one of America's richest families and their connection to the nation's opioid crisis."[4] In the lawsuit, Healey said that eight members of the Sackler family are "personally responsible" for the deception. She alleges they "micromanaged" a "deceptive sales campaign."[9] On January 31, a Massachusetts state judge agreed with The Times and other media organizations, that the entire complaint related to Sussex County v. Purdue, should be made public, in spite of Purdue's efforts to block the release.[10]

Background

In 1995, Purdue Pharma laboratory tests showed that "68% of the oxycodone could be extracted from an OxyContin tablet when crushed".[11][12] A July 1996 study co-authored by Paul D. Goldenheim MD - who later became Purdue's chief medical officer - published in the Journal of Clinical Pharmacology reported that the controlled-release (CR) formulation - by mouth - had a variable duration of action ranging from 10–12 hours. The report by eight authors said that, "[t]reatment with CR oxycodone was safe and effective in this study, and its characteristics will be beneficial in the treatment of pain."[13] The report said that the study was independent of Purdue Pharma.

In 1996, Purdue Pharma "began a massive marketing campaign", based on a "unique claim" for OxyContin, with FDA permission, that, "as a long-acting opioid, it might be less likely to cause abuse and addiction than shorter-acting painkillers like Percocet."[14] By 1998, Purdue's audiotapes, brochures, videotapes, literature and its website "Partners Against Pain", "claimed that the risk of addiction from OxyContin was extremely small."[15][11]

In 2001 New York Times journalist Barry Meier, who is the author of Pain Killer: A Wonder Drug's Trail of Addiction and Death,[16] began investigating Purdue Pharma and OxyContin,[17] then a relatively unknown drug made by a relatively unknown family the Sacklers, who were at that time "one of the wealthiest families in the United States".[14] In an August 24, 2001 taped-interview with three top Purdue executives, CEO Michael Friedman, Howard Udell and Dr. Paul Goldenheim, the executives told Meier that "they had learned of OxyContin’s growing abuse only in early 2000, a statement they also made before congressional committees".[14]

The number of prescriptions of OcyContin rose to more than 14 million in 2001 and 2002 up from 316, 000 prescriptions in 1996. This represented almost $3 billion in sales compared to $44 million in 1996.[11] Purdue directly sponsored and/or gave grants for over "20, 000 pain-related educational programs" influencing doctors' prescribing in the United States from 1996 to July 2002.[11] In 2002 during the United States Senate Committee on Health, Education, Labor, and Pensions Hearing on "OxyContin: balancing risks and benefits", Paul Goldenheim reported that in 2001 alone Purdue spent $200 million marketing OxyContin.[18]: 87 [11]

A 2004 New York Times review of Meier's 2003 book, Pain Killer, described how "For years, doctors who prescribed OxyContin were told that the risk of addiction to the painkiller was less than 1 percent. Only after the drug had devastated thousands of lives was it revealed that this figure, touted as scientific fact, was based on a small study that had no relevance for the general public."[17]

In 2014, the Office of the Attorney General (OAG) of the State of New York began an investigation of Purdue's Abuse and Diversion Detection (ADD) Program and Purdue’s unbranded website www.inthefaceofpain.com.[19] In 2015, Purdue entered into an Assurance of Discontinuance with the New York Attorney General.[19][8]

In a 2015 article in the Annual Review of Public Health, researchers wrote that, "Between 1996 and 2002, Purdue Pharma funded more than 20,000 pain-related educational programs through direct sponsorship or financial grants and launched a multifaceted campaign to encourage long-term use of [opioid painkillers] for chronic non-cancer pain. As part of this campaign, Purdue provided financial support to the American Pain Society, the American Academy of Pain Medicine, the Federation of State Medical Boards, the Joint Commission, pain patient groups, and other organizations. In turn, these groups all advocated for more aggressive identification and treatment of pain, especially use of [opioid painkillers]."[20][21]: 562 

In 2016, investigative journalists Harriet Ryan, Lisa Girion, and Scott Glover of the Los Angeles Times published the results of their extensive investigation into OxyContin, reporting that Purdue had "marketed OxyContin for its supposed ability to provide 12 hours of pain relief", which put it at a competitive advantage over other pain killers.[20] However,"[e]ven before OxyContin went on the market, clinical trials showed many patients weren’t getting 12 hours of relief. Since the drug’s debut in 1996, the company has been confronted with additional evidence, including complaints from doctors, reports from its own sales reps and independent research."[20][22] In response to the series, Senator Edward J. Markey, (D-MASS) asked the DOJ, the FDA, and the Federal Trade Commission to launch an investigation into Purdue Pharma.[22] In 2017, "Purdue sold $1.74 billion of OxyContin...according to Symphony Health Solutions".[2] Governor Andrew Cuomo said, "The opioid epidemic was manufactured by unscrupulous distributors who developed a $400 billion industry pumping human misery into our communities."[2]

On October 30, 2017, The New Yorker published a lengthy exposé on Raymond Sackler, who was the co-founder along with his brother Mortimer Sackler of Purdue Pharma, and the Sackler family,[23] that linked Raymond and his older brother, Arthur Sackler's business acumen with the rise of direct pharmaceutical marketing and eventually to the rise of addiction to OxyContin. The article implies that the Sackler family bears a moral responsibility for the opioid epidemic in the United States.[23][24][25]

By August 2018, the U.S. Food and Drug Administration continued to approve Purdue's "scientific and medical information it has provided to doctors".[2] By 2018, 27 States and Puerto Rico, including New York, U.S. states, counties and cities, including New York City, Bridgeport, New Haven and Waterbury, had filed lawsuits, accusing "Opioid makers and distributors" of "using deceptive marketing to sell the painkillers".[2]

Prior history

A 2004 New York Times review of Meier's 2003 book, Pain Killer, described how "For years, doctors who prescribed OxyContin were told that the risk of addiction to the painkiller was less than 1 percent. Only after the drug had devastated thousands of lives was it revealed that this figure, touted as scientific fact, was based on a small study that had no relevance for the general public."[17] The U.S. Department of Justice investigated the allegations. On May 10, 2007, Purdue Frederick Company Inc, an affiliate of Purdue Pharma, along with 3 company executives, pled guilty to criminal charges of misbranding OxyContin by claiming that it was less addictive and less subject to abuse and diversion than other opioids."[11] In May 2007, John Brownlee, the federal attorney in Roanoke in rural Virginia met privately with Meier to tell him that his August 2001 interview with Friedman, Udell and Goldenheim, had helped "inform" the DOJ's investigation. Meier and a New York Times photographer met the three executives on May 10, 2007, as they had left the federal courthouse in Roanoke, heading to their corporate jet to go back to Connecticut, just before Brownlee's public announcement of their guilty pleas of "misbranding" OxyContin.[2] At their sentencing hearing in July 2007, Judge James P. Jones of the United States District Court sentenced Friedman, Udell and Goldenheim to $34.5 million in fines, "three years’ probation", and "400 hours each of community service in drug treatment programs".[26][27] The holding company, Purdue Frederick, which was "affiliated with Purdue Pharma pleaded guilty to a felony charge that it had fraudulently claimed to doctors and patients that OxyContin would cause less abuse and addiction than competing short-acting narcotics like Percocet and Vicodin."[27] It was fined "$600 million in fines and other payments and was put on five years' probation".[27][2] In 2006, Rudolph W. Giuliani was lead counsel and lead spokesmen for Purdue Pharma during their negotiations with federal prosecutors over charges that the Purdue had misled the public about OxyContin's addictive properties. Purdue was a client of the firm Bracewell & Giuliani. The agreement reached resulted some of Purdue executives paying fines amounting to $634.5 million.[28] According to a May 25, 2018 CNBC article, Rudolph W. Giuliani, who was representing Purdue Pharma at the time, held meetings with Alice S. Fisher who was head of the United States Assistant Attorney General for the Criminal Division from 2005 to 2008. Following these meetings, Fisher "chose not to pursue indictments against Purdue Pharma for their role in opioid abuse".[29] May 10, 2007 Purdue Frederick Company Inc, an affiliate of Purdue Pharma, along with 3 company executives, pleaded guilty to criminal charges of misbranding OxyContin by claiming that it was less addictive and less subject to abuse and diversion than other opioids"[11] after the U.S. Department of Justice investigated the allegations. In May 2007, John Brownlee, the federal attorney in Roanoke in rural Virginia met privately with Meier to tell him that his August 2001 interview with Friedman, Udell and Goldenheim, had helped "inform" the DOJ's investigation. Meier and a New York Times photographer met the three executives on May 10, 2007, as they had left the federal courthouse in Roanoke, heading to their corporate jet to go back to Connecticut, just before Brownlee's public announcement of their guilty pleas of "misbranding" OxyContin.[2] At their sentencing hearing in July 2007, Judge James P. Jones of the United States District Court sentenced Friedman, Udell and Goldenheim to $34.5 million in fines, "three years’ probation", and "400 hours each of community service in drug treatment programs".[27] The holding company, Purdue Frederick, which was "affiliated with Purdue Pharma pleaded guilty to a felony charge that it had fraudulently claimed to doctors and patients that OxyContin would cause less abuse and addiction than competing short-acting narcotics like Percocet and Vicodin."[27] It was fined "$600 million in fines and other payments and was put on five years' probation".[27][2] In May 2007, the company pleaded guilty to misleading the public about Oxycontin's risk of addiction and agreed to pay US$600 million in one of the largest pharmaceutical settlements in U.S. history. The company's president (Michael Friedman), top lawyer (Howard R. Udell) and former chief medical officer (Paul D. Goldenheim) pleaded guilty as individuals to misbranding charges, a criminal violation and agreed to pay a total of US$34.5 million in fines.[30][31] Friedman, Udell and Goldenheim agreed to pay US$19 million, US$8 million and US$7.5 million, respectively. In addition three top executives were charged with a felony and sentenced to 400 hours of community service in drug treatment programs.[32]

According to the NPR, the city of Everett, Washington filed a lawsuit in In February 2017, against Purdue Pharma calling for Purdue to cover the costs of the City's opioid crisis which the city claims Purdue caused through their negligence.[33] In January 2018 New York City filed a "lawsuit seeking $500 million from Purdue and seven other opioid makers and distributors to fight the opioid crisis there".[2] A coalition of 41 States is "investigating the opioid industry".[2][34] In 2016 alone, there were about 3,086 deaths in New York state and over 1,100 in New York City.[2]

On December 20, 2018 George Jepsen, the Connecticut Attorney General, brought a lawsuit against Purdue Pharma et al.[35]

According to a December 2, 2018 article in Vox opioid companies, including Purdue, have faced an "increasing number of lawsuits from cities, counties, and states blaming the drug manufacturers for irresponsibly fostering the current overdose crisis."[20]

According to a January 31, 2019 article in The Guardian, the Oklahoma case against Purdue Pharma will go to trial in May 2019; the first of more than forty states suing Purdue Pharma.[36]

Notes

See also

References

  1. ^ a b c Cortellessa, Eric (November 21, 2018). "Sackler family faces possible criminal charges for role in opioid crisis: New York's Suffolk County sues Jewish multi-billionaire owners of Purdue Pharma, the maker of OxyContin; Connecticut and NY considering pressing charges". Washington, DC: Times of Israel. Retrieved November 21, 2018.
  2. ^ a b c d e f g h i j k l m Stempel, Jonathan (August 14, 2018). "New York sues OxyContin maker Purdue Pharma over opioids". Reuters. Retrieved November 21, 2018.
  3. ^ a b "Hammer on the abusers': Mass. attorney general alleges Purdue". Washington Post. January 15, 2019. Retrieved January 30, 2019.
  4. ^ a b c Frehse, Rob; Marco, Tony (January 30, 2019). "Opioid maker Purdue Pharma fights to prevent documents involving Sackler family from going public". CNN. Retrieved January 30, 2019.
  5. ^ Siemaszko, Corky (June 16, 2018). "They're the first family of pharma. And now they're being sued". NBC News. Retrieved February 2, 2019.
  6. ^ a b Basler, Cassandra (October 25, 2018). "Suffolk County Sues Purdue Pharma Family Over Opioids". Retrieved November 21, 2018.
  7. ^ Keefe, Patrick Radden (October 30, 2017). "The Family That Built an Empire of Pain: The Sackler dynasty's ruthless marketing of painkillers has generated billions of dollars—and millions of addicts". The New Yorker. Retrieved November 21, 2018.
  8. ^ a b "Governor Cuomo and Attorney General Underwood Announce Suit Against Purdue Pharma for Widespread Fraud and Deception in Marketing of Opioid Products". Governor of New York. Albany, NY. August 14, 2018. Retrieved November 21, 2018.
  9. ^ "Family behind OxyContin maker engineered opioid crisis, Massachusetts AG says". CBS News. January 24, 2019. Retrieved February 2, 2019.
  10. ^ Meier, Barry (February 1, 2019). "Sackler Scion's Email Reveals Push for High-Dose OxyContin, New Lawsuit Disclosures Claim". The New York Times. ISSN 0362-4331. Retrieved February 2, 2019.
  11. ^ a b c d e f g Van Zee, Art (February 2009). "The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy". American Journal of Public Health. 99 (2): 221–227. doi:10.2105/AJPH.2007.131714. PMC 2622774. PMID 18799767.
  12. ^ New Drug Application to FDA for OxyContin, Pharmacology Review: 'Abuse Liability of Oxycodone.'. Purdue Pharma (Report). Stamford, CN. 1995.
  13. ^ Sunshine, Abraham; Olson, Nancy Z.; Colon, Ariel; Rivera, Juana; Kaiko, Robert F.; Fitzmartinfirst7=Robert F., Ronald D.; Reder; Goldenheim, Paul D. (July 1996). "Analgesic Efficacy of Controlled‐Release Oxycodone in Postoperative Pain". Journal of Clinical Pharmacology. 36 (7): 595–603. doi:10.1002/j.1552-4604.1996.tb04223.x. PMID 8844441. "Duration of pain relief showed that the 10-, 20-, and 30-mg doses of CR oxycodone had durations of action of 10 to 12 hours compared with IR oxycodone and oxycodone plus APAP (both approximately 7 hours). Typical adverse events, particularly somnolence, occurred in all active treatment groups. Treatment with CR oxycodone was safe and effective in this study, and its characteristics will be beneficial in the treatment of pain." Researchers: Dr. Abraham Sunshine MD, FCP; Ms. Nancy Z. Olson MPS; Dr. Ariel Colon MD; Dr. Juana Rivera MD; Dr. Robert F. Kaiko PhD; Dr. Ronald D. Fitzmartin PhD; Dr. Robert F. Reder MD; Dr. Paul D. Goldenheim MD{{cite journal}}: CS1 maint: numeric names: authors list (link) Wikipedia article Oxycodone: A July 1996 study independent of Purdue Pharma, found the controlled-release formulation (OxyContin, Xtampza ER) had a variable duration of action ranging from 10–12 hours. By mouth (CR): 10–12 hrs
  14. ^ a b c Meier, Barry (June 8, 2018). "Every Time I Thought the Purdue Pharma OxyContin Story Was Over, I Was Wrong: Not only would a previously undisclosed prosecution report surface more than a decade after it was written, but as fate would have it, I would be in it". New York Times. Retrieved November 21, 2018.
  15. ^ "Dispelling the Myths About Opioids", Purdue Pharma, Brochure for physicians, Stamford, CN, 1998
  16. ^ Meier, Barry (October 17, 2003). Pain Killer: A Wonder Drug's Trail of Addiction and Death. Rodale Books. p. 333. ISBN 9781579546380.
  17. ^ a b c Kenneally, Christine (January 4, 2004). "Pain Killer". New York Times. Books in Brief: Nonfiction. Retrieved November 21, 2018.
  18. ^ "Testimony of Paul Goldenheim, Purdue Pharma". Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate. February 12, 2002.
  19. ^ a b "attorney general of the state of new york in the matter of purdue pharma l.p. assurance no.: 15-151 assurance of discontinuance under executive law section 63, subdivision 15" (PDF). Office of the Attorney General (OAG) State of New York. Retrieved November 21, 2018.
  20. ^ a b c d Lopez, German (February 12, 2018). "The maker of OxyContin will finally stop marketing the addictive opioid to doctors: The move comes after the company helped cause an ongoing drug overdose crisis that has killed hundreds of thousands". VOX. Retrieved November 21, 2018. Purdue's decision to stop marketing OxyContin comes at a convenient time for the company. [...]. At the same time, the company's profits from OxyContin, as well as opioid prescriptions in general, have recently dropped — OxyContin generated $1.8 billion in 2017, down from $2.8 billion in 2012, Bloomberg reported.
  21. ^ "The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction". Annual Review of Public Health. 36: 559–74. January 12, 2015. doi:10.1146/annurev-publhealth-031914-122957. PMID 25581144. {{cite journal}}: Unknown parameter |authors= ignored (help)
  22. ^ a b Harriet, Ryan (May 27, 2016). "Senator calls for investigation of Purdue Pharma following Times story on OxyContin". Los Angeles Times. Retrieved November 21, 2018.
  23. ^ a b Keefe, Patrick Radden (October 23, 2017). "The Family That Built an Empire of Pain". The New Yorker. ISSN 0028-792X. Retrieved 2017-10-25.
  24. ^ Langer, Emily (July 21, 2017). "Raymond Sackler, philanthropist and maker of OxyContin, dies at 97". Washington Post. Retrieved December 29, 2017.
  25. ^ "Sackler Blood Money disgraces museums". theguardian.com. Retrieved 2018-10-17.
  26. ^ "Suffolk v. Purdue et al" (PDF). July 19, 2017. Retrieved November 21, 2018.
  27. ^ a b c d e f Meier, Barry (July 21, 2007). "3 Executives Spared Prison in OxyContin Case". New York Times. Retrieved November 21, 2018.
  28. ^ Meier, Barry (June 19, 2007). "Big Part of OxyContin Profit Was Consumed by Penalties". The New York Times.
  29. ^ "Origins of an epidemic: Purdue Pharma knew opioids were widely abused". May 25, 2018. Retrieved January 30, 2019.
  30. ^ Sue Lindsey, (May 11, 2007) OxyContin Maker, Execs Guilty of Deceit USA Today reproducing and Associated Press report
  31. ^ Barry Meier, (May 11, 2007) "In Guilty Plea, OxyContin Maker to Pay $600 Million", New York Times
  32. ^ "domain-b.com : Purdue Pharma fined $634 million for OxyContin deaths; executives punished". www.domain-b.com. July 22, 2007. Retrieved 22 October 2017.
  33. ^ "U.S. City Sues OxyContin Maker for Contributing to Opioid Crisis". NPR. February 3, 2017. Retrieved November 21, 2018.
  34. ^ NYC sues big pharma for $500M for role in opioid epidemic By Michael Gartland January 23, 2018
  35. ^ State of Connecticut v Purdue (PDF), December 20, 2018, p. 30, retrieved January 2, 2019, State of Connecticut, : Superior court plaintiff, : : judicial district : of Hartford v. Purdue Pharma L.P., Purdue Pharma Inc., Richard Sackler, Theresa Sackler, Kathe Sackler, Jonathan Sackler, Mortimer D.A. Sackler, Beverly Sackler, David Sackler, Ilene Sackler Lefcourt, Frank Peter Boer, Paulo Costa, Cecil Pickett, Ralph Snyderman, Judy Lewent, John Stewart and Mark Timney
  36. ^ Walters, Joanna (January 31, 2019). "Opioids: Boston trial opens what could be year of reckoning for executives". The Guardian. ISSN 0261-3077. Retrieved February 2, 2019.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Massachusetts_v._Purdue&oldid=881485155"